{"brief_title": "A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis", "brief_summary": "The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.", "detailed_description": "In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "L-743,872", "criteria": "Inclusion Criteria You may be eligible for this study if you: - Are an 18- to 65-year-old man with candidal esophagitis.", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00005921.xml"}